News Releases

News & Events

News Releases

Synteract Honored with Five Life Science Leader 2016 CRO Leadership Awards

SAN DIEGO – May 10, 2016 – Synteract, a full-service, international contract research organization (CRO), is the recipient of five 2016 CRO Leadership Awards from Life Science Leader magazine. For the 2016 CRO Leadership Awards, Life Science Leader magazine teamed up with Industry Standard Research (ISR) to develop a benchmarking survey, taken by biopharma clients, which would determine the award recipients.

More than 65 contract research organizations were assessed for 27 performance metrics in the survey. Survey respondents were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with contract research organizations within the past 18 months; 2200 service encounters were captured. This level of qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data.

Life Science Leader established five core categories: capabilities, compatibility, expertise, quality and reliability. To win, customers must have judged the CROs as top performers or as exceeding expectations. CROs could win in up to three groupings – big pharma, small pharma or overall, which combined the scores from both big and small pharma. Synteract won in the following categories:

  • Compatibility (Overall)
  • Capabilities (Big Pharma)
  • Compatibility (Big Pharma)
  • Expertise (Big Pharma)
  • Quality (Big Pharma)

Life Science Leader is proud to be working with ISR Reports to honor those CROs that have  proven themselves to be the top performers in these categories,” said Ed Miseta, executive editor for Life Science Leader.  “The winners were decided by looking at 27 different performance metrics, as rated by decision-making executives at biopharmaceutical companies. The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being a top performer in any of these categories shows expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”

This is the second time that Synteract has been honored with LSL CRO awards. In 2015, Synteract won in the emerging pharma category for innovation, reliability, productivity and regulatory expertise.

Synteract CEO Wendel Barr said, “Our international team of experts deserves these awards for the fantastic jobs they do in supporting our biopharma clients. We are very pleased to be acknowledged in this manner by both the publication and our clients. Thank you!”

For more information about Synteract's services for pharmaceutical and biopharmaceutical companies, click here

About Synteract                                                                             

Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

# # #

Beth Walsh


Contact Synteract

Tell us how to stay in touch with you: